© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to May
sel. CCR2 chemokine receptor antagonist
oral efficacy (25 mpk BID) in inflamm. models
from PK opt. of prior candidate
ACS Med. Chem. Lett., May 25, 2021
Bristol Myers Squibb, Princeton, NJ
The BMS CCR2 inhibitor, BMS-753426, is a potent, oral follow-up molecule to prior clinical candidate, BMS-741672. A small change from a methyl and isopropyl-substituted tertiary amine to a t-butyl secondary amine…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.